- Home
- USDE vs ABEO Comparison
USDE vs ABEO Comparison
Compare USDE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USDE | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.0M | 282.5M |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | USDE | ABEO |
|---|---|---|
| Price | $9.86 | $4.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.33 | $4.00 |
| 52 Week High | $17.50 | $7.65 |
Technical Indicators
Market Signals| Indicator | USDE | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 33.75 |
| Support Level | $5.87 | $4.26 |
| Resistance Level | $17.50 | $5.83 |
| Average True Range (ATR) | 1.14 | 0.22 |
| MACD | -0.63 | -0.01 |
| Stochastic Oscillator | 5.12 | 15.91 |
Price Performance
Historical ComparisonAbout USDE StablecoinX Inc. Class A Common Stock
StableCoinX Inc is a newly-formed validator and infrastructure business expected to operate infrastructure and staking services, running validators and related technical services for the Ethena protocol. The company is expected to adopt a multi-year treasury strategy to build a reserve of ENA, the Ethena protocol's native token.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.